{"id":"W4410804826","doi":"10.1200/jco.2025.43.16_suppl.1003","title":"INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Oncology; Internal medicine; Pharmacology; Gynecology; Cancer; Estrogen receptor; Metastatic breast cancer; Breast cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002608454,0.001531666,0.001886566,0.0005090364,0.000361411,0.001822899,0.001363764,0.001369416,0.004757105],"category_scores_gemma":[0.001352604,0.0006070082,0.002296372,0.0004998785,0.000801878,0.0008395087,0.000563158,0.003715084,0.001059646],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001159695,"about_ca_system_score_gemma":0.001994919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008667843,"about_ca_topic_score_gemma":0.002913246,"domain_scores_codex":[0.9993399,0.000326845,0.0000300703,0.0001006618,0.00006940183,0.0001330702],"domain_scores_gemma":[0.9992611,0.0001112881,0.0001934946,0.00006294924,0.00006095528,0.0003102507],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8443613,0.01901788,0.006172496,0.001814337,0.003077469,0.0001467374,0.0002405765,0.003741599,0.02848659,0.0006286781,0.01146737,0.08084495],"study_design_scores_gemma":[0.7712873,0.1998717,0.01230188,0.0001291402,0.001796395,0.0003836192,0.00008085518,0.001934408,0.003910009,0.0004458986,0.007803327,0.00005543042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9575761,0.008551558,0.00212727,0.001152454,0.0005526897,0.007914538,0.009137253,0.0004883909,0.0124998],"genre_scores_gemma":[0.9649434,0.003214906,0.002660966,0.001561911,0.000351877,0.006283406,0.01525914,0.0001238558,0.005600579],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004757105,"threshold_uncertainty_score":0.01591408,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03850210338684483,"score_gpt":0.4100375686141059,"score_spread":0.3715354652272611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}